期刊文献+

儿童横纹肌肉瘤预后的影响因素分析 被引量:1

Prognostic Analysis of Pediatric Rhabdomyosarcoma
下载PDF
导出
摘要 目的:探讨儿童横纹肌肉瘤(RMS)的临床病理特征及预后影响因素。方法:回顾性分析我科93例RMS患儿的临床及生存资料,引入患儿性别、年龄、肿瘤大小、原发部位、组织学类型、COG-stage分期、COG-group分期、危险度分组和手术情况共9个因素。采用COX回归模型进行多因素分析,确立影响预后的因素,采用Kaplan-Meier生存曲线和Log-rank检验比较影响因素与生存率的关系。结果:全组1年、3年、5年生存率分别为90.3%、62.0%、43.1%,总体中位生存期为47.28个月。多因素分析显示组织学类型、原发部位、group分期和是否手术切除是儿童RMS预后的影响因素。生存分析提示不同组织学类型、原发部位、group分期及是否手术切除的预后差异均有统计学意义(均P<0.001)。结论:儿童RMS预后的影响因素有组织学类型、原发部位、group分期和是否手术切除,通过此分析能为预后判断和临床治疗强度的选择提供依据。 Objective: To explore the clinicopathological characteristics and prognostic factors of pediatric rhabdomyosarcoma (RMS). Methods: The clinical data of 93 patients with RMS were reviewed and analyzed including gender, age, tumor size, primary site, histological subtypes, COG-staging, COG-grouping, risk classification and option of surgery. COX regression model was used to do multivariate analysis to identify the independent prognostic factors. The relationship between the above factors and the survival rate was analyzed by Kaplan-Meier curve and Log-rank test. Results: The survival rates of one-year, three-year and five-year for patients with RMS were 90.3%, 62.0% and 43.1%, respectively. The median overall survival time was 47.28 months. Multivariate analysis showed that the histological subtypes, primary site, COG-grouping and option of surgery were independent prognostic factors. The survival analysis showed that there were significant differences in the prognostic differences among the histological subtypes, primary site, COG-grouping and option of surgery (all P〈 0.001). Conclusion: The independent prognostic factors for pediatric RMS included histological subtypes, primary site, COG-grouping and option of surgery. These clinicopatholgical features can be used to predict the prognosis and provide basis for clinical treatment.
作者 郭芬 赵强
出处 《天津医药》 CAS 北大核心 2011年第12期1105-1107,共3页 Tianjin Medical Journal
关键词 横纹肌肉瘤 回归分析 存活率分析 回顾性研究 预后 儿童 rhabdomyosarcoma regression analysis survival analysis retrospective studies prognosis child
  • 相关文献

参考文献10

  • 1Ognjanovic S, Linabery AM, Charbonneau B,et al. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005[J]. Cancer, 2009,115(18):4218-4226.
  • 2Pappo AS,Shapiro DN,Crist WM,et al.Biology and therapy of pediatric rhabdomyosarcoma[J]. J Clin Oncol,1995,13(8):2123-2139.
  • 3Cfist WM,Anderson JR,Meza JL,et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease[J].J Clin Oncol,2001,19(12):3091-310.
  • 4Carli M,Colombatti R,Oberlin O,et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma:final results and analysis of prognostic factors[J].J Clin Oncol, 2004,22 ( 23 ) :4787 -4794.
  • 5汤静燕,潘慈,徐敏,薛惠良,陈静,董璐,周敏,顾龙君,陈其民.儿童横纹肌肉瘤RS-99诊断治疗方案远期临床随访报告[J].中华医学杂志,2009,89(2):121-123. 被引量:12
  • 6Hosoi H, Teramukai S, Matsumoto Y,et al. A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan[J].J Clin Oncol,2007,12(2):137-145.
  • 7Parham DM, Ellison DA. Rhabdomyosarcomas in adults and children: an update[J].Arch Pathol Lab Med,2006,130(10): 1454-1465.
  • 8Leaphart C, Rodeberg D. Pediatric surgical oncology: Management of rhabdomyosarcoma[J].Surgical Oncology,2007,16 ( 3 ): 173 - 185.
  • 9Maurer HM,Beltangady M,Gehen EA,et al. The intergroup rhabdomyosarcoma study, II [J].Cancer, 1993,71 (5); 1904-1922.
  • 10Daya H, Chan H, Sirkin W, et al. Pediatric rhabdomyosarcoma of the head and neck [J].Arch Otolaryngel Head Neck Surg,2000,126 (4):468-472.

二级参考文献11

  • 1Newton WA Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification:an Intergroup Rhabdomyosarcoma Study. Cancer,1995,76:1073-1085.
  • 2Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV : results for patients with nonmetastatic disease. J Clin Oncol,2001, 19:3091-3102.
  • 3Sandler E, Lyden E, Ruymann F, et al. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol, 2001,37:442-448.
  • 4Navid F, Santana VM, Billups CA, et al. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children' s Research Hospital experience. Cancer, 2006, 106 : 1846-1856.
  • 5Breiffeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosareoma Study Group. J Pediatr Hematol Oncol,2001, 23:225-233.
  • 6Smith SC, Lindsley SK, Felgenhauer J, et al. Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma. Hematol Oncol, 2003, 25 : 774-779.
  • 7Douglas JG, Amdt CA, Hawkins DS, et al. Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood, 2007, 43: 1045 -1050.
  • 8Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma-a report from the IRSG. Int J Radiat Oneol Biol Phys,2001,51:718-728.
  • 9Bisogno G, De Rossi C, Gamboa Y, et al. Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP soft tissue sarcoma committee ,2008,50 : 1154-1158.
  • 10Cecchetto G, Bisogno G, Treuner J, et al. Role of surgery for nonmetastatic abdominal rhabdomyosarcomas: a report from the Italian and German Soft Tissue Cooperative Groups Studies. Cancer,2003, 97 : 1974-1980.

共引文献11

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部